Get the Stockscreener App
707.51
1.30%
9.07
After Hours:
707.51
Regeneron Pharmaceuticals Inc stock is traded at $707.51, with a volume of 932.67K.
It is up +1.30% in the last 24 hours and down -0.35% over the past month.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$698.44
Open:
$698.63
24h Volume:
932.67K
Relative Volume:
1.12
Market Cap:
$77.35B
Revenue:
$14.20B
Net Income/Loss:
$4.41B
P/E Ratio:
18.48
EPS:
38.28
Net Cash Flow:
$3.54B
1W Performance:
+1.26%
1M Performance:
-0.35%
6M Performance:
-37.47%
1Y Performance:
-27.31%
1-Day Range:
$696.43
$729.75
1-Week Range:
$673.15
$729.75
52-Week Range:
$642.00
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
707.51 | 77.35B | 14.20B | 4.41B | 3.54B | 38.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.29 | 125.39B | 11.02B | -535.60M | -978.00M | -2.20 |
|
ARGX
Argen X Se Adr
|
594.21 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
244.52 | 31.65B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
247.07 | 26.47B | 3.32B | -860.46M | -1.04B | -8.32 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Mission Wealth Management LP Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Cullen Frost Bankers Inc. Purchases 5,838 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron, Sanofi presents results from ADEPT Phase 2/3 trial on Dupixent - TipRanks
2025-03-09 | Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. LawsuitREGN | NDAQ:REGN | Press Release - Stockhouse Publishing
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade - sharewise
Schaper Benz & Wise Investment Counsel Inc. WI Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Personal CFO Solutions LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Atlantic Union Bankshares Corp Boosts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Generali Investments CEE investicni spolecnost a.s. Makes New $1.16 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade - The Motley Fool
Callan Family Office LLC Acquires New Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGN Deadline: Rosen Law Firm Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
Regeneron Pharmaceuticals Inc (REGN) Announces Promising Results for Dupixent in Treating Bullous Pemphigoid - GuruFocus.com
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD - The Manila Times
Can Dupixent Transform Rare Skin Disease Treatment? New Trial Data Reveals Breakthrough - StockTitan
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Andra AP fonden - MarketBeat
Edgestream Partners L.P. Acquires 8,475 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
3,450 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Greenwoods Asset Management Hong Kong Ltd. - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by E Fund Management Co. Ltd. - MarketBeat
Bay Colony Advisory Group Inc d b a Bay Colony Advisors Sells 545 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Assetmark Inc. Has $71.93 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Charles Schwab Investment Management Inc. Has $495.64 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Steward Partners Investment Advisory LLC Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Levi & Korsinsky Reminds Regeneron Pharmaceuticals, Inc. - GlobeNewswire
SBI Securities Co. Ltd. Invests $464,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Fisher Asset Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Oak Grove Capital LLC Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron’s Gene Therapy DB-OTO Trial Shows Promising Hearing Improvement - The Hearing Review
(REGN) Technical Pivots with Risk Controls - Stock Traders Daily
REGN DEADLINE ALERT: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Regeneron - The Bakersfield Californian
Deadline Soon: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - Business Wire
Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action ... - The Bakersfield Californian
Candriam S.C.A. Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Victory Capital Management Inc. Purchases 43,282 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals - Nasdaq
SVB Wealth LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Los Angeles Capital Management LLC - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
REGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, I - The National Law Review
Is Regeneron Pharmaceuticals Stock Underperforming the Dow? - Nasdaq
Regeneron’s (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices– Hagens Berman - GlobeNewswire
Regeneron’s (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices - The Bakersfield Californian
Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) Urged to Join Class - Bluefield Daily Telegraph
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Is Regeneron Pharmaceuticals Stock Underperforming The Dow? - Barchart
Libtayo® (cemiplimab for injection) Letter of Intent Signed by Regeneron Canada and pan-Canadian Pharmaceutical Alliance for Advanced Non-Small Cell Lung Cancer and Locally Advanced Basal Cell Carcinoma - Canada NewsWire
Aigen Investment Management LP Buys 5,644 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron receives positive CHMP opinion for linvoseltamab in multiple myeloma - PMLiVE
Regeneron Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025REGN - PR Newswire
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.09%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):